Menu Search
Equities

Genovis AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5GV:FRA

Genovis AB

Actions
  • Price (EUR)1.80
  • Today's Change-0.056 / -3.01%
  • Shares traded250.00
  • 1 Year change-23.40%
  • Beta1.8730
Data delayed at least 15 minutes, as of Feb 11 2026 07:07 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

  • Revenue in SEK (TTM)116.63m
  • Net income in SEK21.19m
  • Incorporated1999
  • Employees36.00
  • Location
    Genovis ABMedicon Village, Scheelevagen 2LUND 223 63SwedenSWE
  • Phone+46 46101230
  • Fax+46 46128020
  • Websitehttps://www.genovis.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.